StemCell Therapy

The "Epigenetic Market Report: Trends, Forecast, and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.

The future of the epigenetic market looks promising with opportunities in the pharmaceutical and biotechnology industries. The global epigenetic market is expected to grow with a CAGR of 14% from 2019 to 2024. The major growth drivers for this market are declining sequencing costs and time, increasing research activities and availability of government funding, and rising cancer prevalence.

A report of more than 150 pages is developed to help in your business decisions. To learn the scope of, benefits, companies researched and other details of the epigenetic market, then read this report.

Some of the features of Global Epigenetic Market 2019-2024: Trends, Forecast, and Opportunity Analysis include:

This report answers the following 11 key questions:

Q.1 What are some of the most promising potential, high-growth opportunities for the global epigenetic market by product, application, technology, and region?

Q.2 Which segments will grow at a faster pace and why?

Q.3 Which regions will grow at a faster pace and why?

Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the epigenetic market?

Q.5 What are the business risks and threats to the epigenetic market?

Q.6 What are emerging trends in this epigenetic market and the reasons behind them?

Q.7 What are some changing demands of customers in the epigenetic market?

Q.8 What are the new developments in the epigenetic market? Which companies are leading these developments?

Q.9 Who are the major players in this epigenetic market? What strategic initiatives are being implemented by key players for business growth?

Q.10 What are some of the competitive products and processes in this epigenetic area and how big of a threat do they pose for loss of market share via material or product substitution?

Q.11 What M & A activities have taken place in the last 5 years in epigenetic market?

Key Topics Covered:

1. Executive Summary

2. Market Background and Classifications

2.1: Introduction, Background, and Classifications

2.2: Supply Chain

2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2013 to 2024

3.1: Macroeconomic Trends and Forecast

3.2: Global Epigenetic Market: Trends and Forecast

3.3: Global Epigenetic Market by Product Type

3.3.1: Enzymes

3.3.2: Kits

3.3.3: Reagents

3.3.4: Bioinformatics Tools

3.4: Global Epigenetic Market by Application

3.4.1: Oncology

3.4.2: Non Oncology

3.5: Global Epigenetic Market by End Use Industry

3.5.1: Pharmaceutical

3.5.2: Biotechnology

3.5.3: Others

3.6: Global Epigenetic Market by Technology

3.6.1: DNA Methylation

3.6.2: Histone Methylation

3.6.3: Histone Acetylation

3.6.4: Large Noncoding RNA

3.6.5: MicroRNA Modification

3.6.6: Chromatin structures

3.6.7: Others

4. Market Trends and Forecast Analysis by Region

4.1: Global Epigenetic Market by Region

4.2: North American Epigenetic Market

4.2.1: Market by Product: Enzymes, Instruments and Consumables, Kits, Reagents, and Bioinformatics

Tools

4.2.2: Market by Application: Oncology and Non Oncology

4.2.3: Market by End Use Industry: Pharmaceutical, Biotechnology. And Others

4.2.4: Market by Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large

Noncoding RNA, MicroRNA Modification, Chromatin Structures, and Others

4.3: European Epigenetic Market

4.3.1: Market by Product: Enzymes, Instruments and Consumables, Kits, Reagents, and Bioinformatics

Tools

4.3.2: Market by Application: Oncology and Non Oncology

4.3.3: Market by End Use Industry: Pharmaceutical, Biotechnology. And Others

4.3.4: Market by Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large

Noncoding RNA, MicroRNA Modification, Chromatin Structures, and Others

4.4: APAC Epigenetic Market

4.4.1: Market by Product: Enzymes, Instruments and Consumables, Kits, Reagents, and Bioinformatics

Tools

4.4.2: Market by Application: Oncology and Non Oncology

4.4.3: Market by End Use Industry: Pharmaceutical, Biotechnology. And Others

4.4.4: Market by Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large

Noncoding RNA, MicroRNA Modification, Chromatin Structures, and Others

4.5: Row Epigenetic Market

4.5.1: Market by Product: Enzymes, Instruments and Consumables, Kits, Reagents, and Bioinformatics

Tools

4.5.2: Market by Application: Oncology and Non Oncology

4.5.3: Market by End Use Industry: Pharmaceutical, Biotechnology. And Others

4.5.4: Market by Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large

Noncoding RNA, MicroRNA Modification, Chromatin Structures, and Others

5. Competitor Analysis

5.1: Product Portfolio Analysis

5.2: Market Share Analysis

5.3: Operational Integration

5.4: Geographical Reach

5.5: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

6.1: Growth Opportunity Analysis

6.1.1: Growth Opportunities for Global Epigenetic Market by Product Type

6.1.2: Growth Opportunities for Global Epigenetic Market by Application

6.1.3: Growth Opportunities for Global Market by End Use Industry

6.1.4: Growth Opportunities for Global Market by Technology

6.1.5: Growth Opportunities for Global Epigenetic Market by Region

6.2: Emerging Trends in Global Epigenetic Market

6.3: Strategic Analysis

6.3.1: New Product Development

6.3.2: Capacity Expansion of Global Epigenetic Market

6.3.3: Mergers, Acquisitions and Joint Ventures in the Global Market

7. Company Profiles of Leading Players

7.1: Illumina

7.2: Thermo Fisher Scientific

7.3: Merck Millipore

7.4: Abcam

7.5: Active Motif

7.6: Bio-Rad

See original here:
Global Epigenetic Market Expected to Grow with a CAGR of 14%, 2019-2024 - ResearchAndMarkets.com - Benzinga

Massachusetts is located in the northeastern region of the continental United States. Formally known as the Commonwealth of Massachusetts, the state has a long and storied history as one of America's original thirteen colonies. It was way back in the year 1620 that the first Pilgrims arrived in Plymouth aboard the Mayflower to begin their lives in the New World. Many years later, in 1782, Massachusetts became the sixth state to join the union. All these years later Massachusetts is known as a state which continues to play an integral role in a variety of integral aspects of modern American life especially in regards to the fields of politics, the economy, arts, and culture, as well as national identity.

With a slew of nicknames including the Old Colony State, Baked Bean State, and Puritan State, Massachusetts comprises a total area of 10,565 square miles. The state is currently home to a population of approximately 6,939,373 people and it's capital city, Boston, boosts the highest population rate of any urban center in New England. The leading industries in Massachusetts include biotechnology, maritime trade, engineering, information technology, finance, tourism, as well as higher education.

Biotechnology involves using technological methods in order to modify or alter the biological elements of an organism and/or living system(s). This is done as a means of creating brand new products or processes. Practical examples of biotechnology include the production of various hormones and antibiotics. A number of related scientific disciplines that often work hand in hand with biotechnology include such related fields as biomedical engineering and molecular biology.

Massachusetts' capital city, Boston, is the hub for the biotechnology industry in the state. The city, as well as the neighboring community of Cambridge, are both home to nearly a thousand biotech companies. One of the reasons for this is the large number of universities located in the area. Among the renowned institutes to have facilities in this part of Massachusetts is the Whitehead Institute for Biomedical Research and the Wyss Institute for Biologically Inspired Engineering. Local biotech companies in Massachusetts include ImmunoGen, Boston Scientific, and Vaxess Technologies.

Massachusetts' coastline on the Atlantic Ocean measures approximately 1,500 miles in length. This is the key reason why the state and many of the people who live there have had a long and illustrious relationship with the sea. For many years marine trade has played a vital part in Massachusetts' domestic economy. Local sports in the state have long enabled Americans to trade with communities in such far-flung parts of the world as China and the Caribbean.

For many years, fishing has been an important industry for those residents living on the Atlantic coast of the state. In the nineteenth century, for example, the New England area benefitted considerably from a boom in whaling activities. During this time whales were hunted for food as well as for the valuable oil they provided. Although saltwater fish stocks have been diminishing over the years due to factors such as overfishing and climate change, a large number of Massachusetts residents still make their living off the ocean and activities such as fishing and the harvesting of lobster and Atlantic horseshoe crabs. Among the valuable fish species to be found in the ocean waters off Massachusetts include haddock, monkfish, Atlantic cod, summer flounder, and black sea bass.

Engineering involves the use of scientific methods in order to design and create various structures such as roadways, buildings, tunnels, and bridges. One of Massachusetts' greatest advantages in terms of its engineering industry expertise is the sheer number of engineering colleges and educational facilities located within the state. An educated and highly specialized workforce is a key element in the state's collective success in the field of engineering. Some of these top-rated institutions in Massachusetts include the Massachusetts Institute of Technology (MIT), Franklin W. Olin College of Engineering, Wentworth Institute of Technology as well as a variety of universities including Harvard, Boston, and Tufts.

Commonly referred to as IT the field of information technology involves using computers in order to acquire, archive, and access data. Figures indicate that the northeastern state is home to about 1,708 organizations connected to information technology. Examples of IT companies operating in Massachusetts include Bloomer Health Tech and the Health Data Analytics Institute.

Financial companies make up an important part of the state's economy. As of 2015, it was estimated that approximately a dozen Fortune 500 companies are located in Massachusetts. In 2014 CNBC listed Massachusetts as the 25th best state in the U.S. for business. Financial companies operating in the state include names such as Fidelity Investments, Liberty Mutual Group, and the Massachusetts Mutual Life Insurance Company.

According to statistics from 2015, Massachusetts ranked sixth in terms of the most popular destinations for tourists traveling to the U.S. from other countries. Besides Boston, the state capital and largest city in the state, other communities popular with international visitors include Plymouth, where the Pilgrims landed, and Salem, site of the infamous witch trials. Other well known local attractions include a variety of historical, cultural, and recreational sites such as "Little Women" author Louisa May Alcott's Orchard House in Concord, the Boston Tea Party Ships and Museum, New Bedford Whaling Museum, and Lizzie Borden's house in Fall River.

The state is also home to numerous parks and natural attractions such as the Walden Pond State Reservation in Concord, Wellfleet Bay Wildlife Sanctuary, and Nickerson State Park.

Massachusetts has long been one of the top states in terms of being home to a myriad of educational institutes of higher learning. The state is home to Roxbury Latin School which has the distinction of being the oldest school in continuous operation since it was established in 1645. Massachusetts is also home to the oldest public elementary, high school, and boarding schools as well as the oldest college and women's' college in the nation. The number of higher learning institutions located in Massachusetts totals 121.

Schools of note in Massachusetts include not only Harvard and MIT but also Boston College, Northeastern University, Wellesley College, Amherst College, and the University of Massachusetts.

Read more:
What Are The Biggest Industries In Massachusetts? - World Atlas

The 31 rating InvestorsObserver gives to Vir Biotechnology Inc (VIR) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 12 percent of stocks in the Biotechnology industry, VIRs 31 overall rating means the stock scores better than 31 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 31 means the stock is more attractive than 31 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Vir Biotechnology Inc (VIR) stock is trading at $36.76 as of 12:45 PM on Monday, Mar 23, a drop of -$3.00, or -7.55% from the previous closing price of $39.76. The stock has traded between $36.15 and $39.94 so far today. Volume today is low. So far 218,746 shares have traded compared to average volume of 1,059,947 shares.

To see the top 5 stocks in Biotechnology click here.

Read the original here:
Industry Breakdown: Where Does Vir Biotechnology Inc (VIR) Stock Fall in the Biotechnology Field? - InvestorsObserver

MIRAMAR, Fla. , March 19, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today provided guidance on their work to develop a peptide vaccine against the new coronavirus SARS-CoV-2 using the companys proprietary and patented Ii-Key immune system activation technology. This guidance is designed to assist third party groups and government agencies in their evaluation of potential vaccines against this pandemic SARS-CoV-2 virus. The patented NuGenerexImmuno-Oncology (Formerly Antigen Express) Ii-Key technology uses synthetic peptides that mimic essential protein regions from a virus that are chemically linked to the 4-amino acid Ii-Key to ensure robust immune system activation. In particular, the Ii-Key ensures potent activation of CD4+ T cells, which in turn facilitates antibody production to ward off infection. This Ii-Key modification can be applied to any protein fragment of any pathogen to increase the potency of immune stimulation. Generex is working with our partners at EpiVax who have identified such protein fragments or epitopes to generate Ii-Key-SARS 2 peptide vaccines in collaboration with our peptide manufacturing partners. The peptides and Ii-Key are made from naturally occurring amino acids, ensuring an excellent safety profile for Ii-Key peptide vaccines.

Generex President & CEO Joseph Moscato said, Generex wants to let everyone know that we are ready and willing to partner on our coronavirus vaccine development program with government health agencies across the globe. Based on our discussions with numerous people throughout the U.S. government and international health agencies, it is clear that additional information is needed by the authorities about the potential to rapidly create a vaccine using our Ii-Key technology to fight the COVID-19 pandemic. Generex has long standing experience developing Ii-Key peptide vaccines for infectious diseases and cancer, so wehave developeda strategy to design, screen and identify vaccine peptides to any novel pathogenic virus to initiate human clinical trials in 3 to 5 months depending on regulatory agency requirements.We have vaccinated over 300 people with Ii-Key vaccines to demonstrate their safety and their ability to activate the immune response against peptide epitopes. As a public service to expedite the review of the Ii-Key vaccine technology by interested parties, we are providing a summary of safety on our Ii-Key development program from both published peer-reviewed literature as well as from our clinical investigator brochures on our website at Generex.com.

Mr. Moscato continued, We ask that governments, health ministries, and large pharmaceutical companies please take note of the potential for Ii-Key peptide vaccines to slow the spread of the SARS-CoV-2 virus. We are advancing the coronavirus project with our partners in China, and we are available to partner with other countries to develop and commercialize our Ii-Key-SARS-2 vaccine. To date we have been in touch with the VA, BARDA, and HHS in the United States, and we are in communication with the Canadian Ministry of Health, as well as with authorities in Greece, England, Saudi Arabia, Iceland, Indonesia, Philippines, Italy, and Romania for licensing our Ii-Key-SARS-2 peptide vaccines as well as new, patented immunotherapy technology that will provide those countries with co-ownership of the Intellectual Property in their territories. We have engaged Morris L. Reid of Mercury LLC (http://mercuryllc.com) to advise the company on international licensing strategy.

Defeating coronavirus requires a public/private partnership, stated Mr. Reid, Partner at Mercury. Government cannot do it alone and must collaborate with the private sector in order to bring the best innovation to the table.

Mr. Moscatoadded his thoughts on peptide vaccines, stating, We know one thing about vaccines and the immune response, and that is our immune system recognizes antigenic epitopes, which are made of amino acid peptides, and mounts a multicellular response to protect the body from invaders like viruses or cancer. Whether you use attenuated or killed viruses or recombinant proteins, peptides are and have been the primary pathway to create vaccines. Peptide vaccines, especially when linked with the Ii-Key, are proven to generate an immune response, and we have demonstrated the safety of various Ii-Key peptide vaccines in animal models and human clinical trials. Over the years, Generex has developed a proven process to generate rapid peptide vaccines using the latest computational algorithms to select the best peptides to create an immune response, and we can link these peptide epitopes to the Ii-key for a very powerful solution that is cost effective and easy to manufacture on a large scale. Every country in the world needs our Ii-key technology in their national health arsenal not only for this coronavirus, but also to respond to future SARS virus mutations and other potential pandemic viruses that have been on the rise the last 20 years.

Story continues

For further information from government or corporate inquiries please email:covid-19@nugenerexio.com

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

NuGenerex Immuno-Oncology (formerly Antigen Express), a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines based on the CD-4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) is being spun out of Generex as a separate, independent public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Mercks Keytruda) for the treatment of triple negative breast cancer.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato

646-599-6222

Todd Falls

Tel: 1-800-391-6755 Extension 222 Email: investor@generex.com

Excerpt from:
Generex Biotechnology Provides Guidance on the Safety of Ii-Key Peptide Vaccines for the Development of Effective Solutions to the SARS-CoV-2...

About the position

We have a vacancy for a PhD fellow within Food Science in the area of foods of plant origin.

The PhD position is available within the Food Science division at the Department of Biotechnology and Food Science. The project will be related to the research about bioactive compounds that are could be found in plants with emphasis on the utilization of by-products.

The overall aim of the PhD project will be to increase the knowledge from the fields of bioactive compounds found in red vegetables either in their edible parts or by-products from their processing. Phytonutrients that are responsible for their red color have powerful health benefits but are prone to degradation during processing and storage. The PhD candidate will work with various methods of extraction and processing technologies that aim to protect chemical substances like betalains, carotenoids, anthocyanins, polyphenols, flavonoids, saponins.

You will reportto Associate Professor Marcin A. Kurek

Duties of the position

Required selection criteria

The PhD-position's main objective is to qualify for work in research positions. The qualification requirement is completion of a masters degree or second degree (equivalent to 120 credits) with a strong academic background in food science, food processing, food technology, food engineering, food chemistry, food microbiology, biotechnology, vegetable biotechnology or equivalent education with a grade of B or better in terms of NTNUs grading scale. Applicants with no letter grades from previous studies must have an equally good academic foundation. Applicants who are unable to meet these criteria may be considered only if they can document that they are particularly suitable candidates for education leading to a PhD degree.

The appointment is to be made in accordance with the regulations in force concerning State Employees and Civil Servants and national guidelines for appointment as PhD, post doctor and research assistant.

Other qualifications

Personal characteristics

In the evaluation of which candidate is best qualified, emphasis will be placed on education, experience and personal suitability.

We offer

Salary and conditions

PhD candidates are remunerated in code 1017, and are normally remunerated at gross from NOK 479 600 per annum before tax, depending on qualifications and seniority. From the salary, 2% is deducted as a contribution to the Norwegian Public Service Pension Fund.

The period of employment is 3 years with the possibility of 1 year extension with teaching duties.

Appointment to a PhD position requires that you are admitted to the PhD programme in Biotechnology (https://www.ntnu.edu/studies/phbiot) within three months of employment, and that you participate in an organized PhD programme during the employment period.

The engagement is to be made in accordance with the regulations in force concerning State Employees and Civil Servants, and the acts relating to Control of the Export of Strategic Goods, Services and Technology. Candidates who by assessment of the application and attachment are seen to conflict with the criteria in the latter law will be prohibited from recruitment to NTNU. After the appointment you must assume that there may be changes in the area of work.

It is a prerequisite you can be present at and accessible to the institution on a daily basis.

About the application

Publications and other scientific work must follow the application. Please note that applications are only evaluated based on the information available on the application deadline. You should ensure that your application shows clearly how your skills and experience meet the criteria which are set out above.

Joint works will be considered. If it is difficult to identify your contribution to joint works, you must attach a brief description of your participation.

General information

A good work environment is characterized by diversity. We encourage qualified candidates to apply, regardless of their gender, functional capacity or cultural background.

The city of Trondheim is a modern European city with a rich cultural scene. Trondheim is the innovation capital of Norway with a population of 200,000. The Norwegian welfare state, including healthcare, schools, kindergartens and overall equality, is probably the best of its kind in the world. Professional subsidized day-care for children is easily available. Furthermore, Trondheim offers great opportunities for education (including international schools) and possibilities to enjoy nature, culture and family life and has low crime rates and clean air quality.

NTNU is committed to following evaluation criteria for research quality according to The San Francisco Declaration on Research Assessment - DORA.

As an employeeatNTNU, you must at all times adhere to the changes that the development in the subject entails and the organizational changes that are adopted.

Information Act (Offentleglova), your name, age, position and municipality may be made public even if you have requested not to have your name entered on the list of applicants.

If you have any questions about the position, please contact Associate Professor Marcin A. Kurek, email: marcin.kurek@ntnu.no

Please submit your application electronically via jobbnorge.no with your CV, diplomas and certificates. Applications submitted elsewhere will not be considered. Diploma Supplement is required to attach for European Master Diplomas outside Norway. Chinese applicants are required to provide confirmation of Master Diploma from China Credentials Verification (CHSI).

If you are invited for interview you must include certified copies of transcripts and reference letters. Together with the application we request up to one page Personal motivation letter for the position.

Please refer to the application number NV-41/20 when applying.

Application deadline: 20.04.2020

NTNU - knowledge for a better world

The Norwegian University of Science and Technology (NTNU) creates knowledge for a better world and solutions that can change everyday life.

Department of Biotechnology and Food Science

Our activities contribute to increased exploitation of existing and new ingredients for sustainable food production as well as next-generation energy solutions and medical technology. We educate graduates for a wide range of careers in industry, public administration and academia. The Department of Biotechnology and Food Science is one of eight departments in the Faculty of Natural Sciences.

Deadline 20th April 2020Employer NTNU - Norwegian University of Science and TechnologyMunicipality TrondheimScope FulltimeDuration TemporaryPlace of service Trondheim

Originally posted here:
PhD Fellow within Food Science in the Area of Food of Plant Origin job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY -NTNU | 201301 - Times...

Ibio Inc (IBIO) is near the middle in its industry group according to InvestorsObserver. IBIO gets an overall rating of 57. That means it scores higher than 57 percent of stocks. Ibio Inc gets a 61 rank in the Biotechnology industry. Biotechnology is number 15 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Ibio Inc (IBIO) stock has risen 60.53% while the S&P 500 is down -4.94% as of 9:44 AM on Wednesday, Mar 18. IBIO has gained $0.69 from the previous closing price of $1.14 on volume of 5,817,991 shares. Over the past year the S&P 500 is lower by -15.12% while IBIO has gained 103.33%. IBIO lost -$1.35 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Continued here:
Industry Breakdown: Where Does Ibio Inc (IBIO) Stock Fall in the Biotechnology Field? - InvestorsObserver

SAN FRANCISCO, March 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc.(VIR) today announced that it has signed a letter of intent with Biogen Inc. (BIIB) for the development and clinical manufacturing of human monoclonal antibodies for the potential treatment of COVID-19, the disease caused by the SARS-CoV-2 virus. Because of the urgency of the situation, the companies have begun work while a Clinical Development and Manufacturing Agreement is being negotiated. Subject to the completion of a definitive agreement, Biogen would continue cell line development, process development, and clinical manufacturing activities in order to advance the development of Virs proprietary antibodies.

These exceptional circumstances presented by the threat of COVID-19 require that we work with great urgency in the interest of the public good, said George Scangos, Ph.D., CEO, Vir. Biogen is one of the global leaders in cell line and process development for advanced biologics; tapping into their capabilities will provide us with a U.S. base for supply and manufacture of antibody therapies.

Vir has identified a number of monoclonal antibodies that bind to SARS-CoV-2, which were isolated from individuals who had survived a SARS (Severe Acute Respiratory Syndrome) infection. The company is conducting research to determine if its antibodies, or additional antibodies that it may be able to identify, can be effective as treatment and/or prophylaxis against SARS-CoV-2.

About Virs Antibody Platform

Vir has a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. The platform is used to identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. Vir engineers the fully human antibodies that it discovers to enhance their therapeutic potential. This platform has been used to identify and develop antibodies for pathogens including Ebola (mAb114, currently in use in theDemocratic Republic of Congo), hepatitis B virus, influenza A, malaria, and others.

AboutVir Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of five product candidates targeting hepatitis B virus, influenza A, human immunodeficiency virus, and tuberculosis. For more information, please visit http://www.vir.bio.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend, potential and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the companys efforts to neutralize the SARS-CoV-2 virus and identify additional potential therapies for SARS-CoV-2, its ability to address the emerging public health epidemic, and its ability to enter into an agreement with Biogen, and its ability to secure a U.S. base for supply and manufacture of antibody therapies. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, challenges in neutralizing SARS-CoV-2, difficulty in reaching a definitive agreement with Biogen, challenges of collaborating with other companies or government agencies, and challenges in accessing manufacturing capacity. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Virs filings with theU.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Story continues

Contact:Vir Biotechnology, Inc.Investors Neera Ravindran, MDHead of Investor Relations & Strategic Communications nravindran@vir.bio+1-415-506-5256

Media Lindy Devereux Scient PR lindy@scientpr.com +1-646-515-5730

Read this article:
Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19 - Yahoo Finance

The global Biotechnology Algae Cultivation Process (Micro Algae) market reached ~US$ xx Mn in 2018 and is anticipated grow at a CAGR of xx% over the forecast period 2019-2029. In this Biotechnology Algae Cultivation Process (Micro Algae) market study, the following years are considered to predict the market footprint:

The business intelligence study of the Biotechnology Algae Cultivation Process (Micro Algae) market covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). In a bid to recognize the growth prospects in the Biotechnology Algae Cultivation Process (Micro Algae) market, the market study has been geographically fragmented into important regions that are progressing faster than the overall market. Each segment of the Biotechnology Algae Cultivation Process (Micro Algae) market has been individually analyzed on the basis of pricing, distribution, and demand prospect for the following regions:

Each market player encompassed in the Biotechnology Algae Cultivation Process (Micro Algae) market study is assessed according to its market share, production footprint, current launches, agreements, ongoing R&D projects, and business tactics. In addition, the Biotechnology Algae Cultivation Process (Micro Algae) market study scrutinizes the strengths, weaknesses, opportunities and threats (SWOT) analysis.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2310558&source=atm

On the basis of age group, the global Biotechnology Algae Cultivation Process (Micro Algae) market report covers the footprint, and adoption pattern of the segments including

The key players covered in this studyCellanaEcodunaAlgenol BiofuelsSolix BiofuelsSapphire EnergySolazymeSeambioticLGemCyanotechDENSOMialgaeNeoalgae

Market segment by Type, the product can be split intoEuglenophyta (Euglenoids)Chrysophyta (Golden-Brown Algae and Diatoms)Pyrrophyta (Fire Algae)Chlorophyta (Green Algae)Rhodophyta (Red Algae)Paeophyta (Brown Algae)Xanthophyta (Yellow-Green Algae)Others

Market segment by Application, split intoFoodFertilizer and AgarPollution ControlEnergy Production

Market segment by Regions/Countries, this report coversUnited StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Biotechnology Algae Cultivation Process (Micro Algae) status, future forecast, growth opportunity, key market and key players.To present the Biotechnology Algae Cultivation Process (Micro Algae) development in United States, Europe and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Biotechnology Algae Cultivation Process (Micro Algae) are as follows:History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2310558&source=atm

What insights readers can gather from the Biotechnology Algae Cultivation Process (Micro Algae) market report?

The Biotechnology Algae Cultivation Process (Micro Algae) market report answers the following queries:

Why Choose Biotechnology Algae Cultivation Process (Micro Algae) Market Report?

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2310558&licType=S&source=atm

For More Information Kindly Contact:

marketresearchhub.com

Mr. Nachiket Ghumare,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Follow this link:
Emerging Opportunities in Biotechnology Algae Cultivation Process (Micro Algae) Market with Current Trends Analysis - Packaging News 24

The 56 rating InvestorsObserver gives to Capricor Therapeutics Inc (CAPR) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 60 percent of stocks in the Biotechnology industry, CAPRs 56 overall rating means the stock scores better than 56 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Capricor Therapeutics Inc (CAPR) stock is trading at $1.12 as of 11:11 AM on Wednesday, Mar 18, a decline of -$0.05, or -4.27% from the previous closing price of $1.17. Volume today is above average. So far 1,088,965 shares have traded compared to average volume of 154,691 shares. The stock has traded between $1.05 and $1.45 so far today.

To see InvestorsObserver's Sentiment Score for Capricor Therapeutics Inc click here.

Read more from the original source:
How Does Capricor Therapeutics Inc (CAPR) Stock Compare to Other Stocks in Biotechnology? - InvestorsObserver

The 50 rating InvestorsObserver gives to DBV TECHNOLOGIE/S ADR (DBVT) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 47 percent of stocks in the Biotechnology industry, DBVTs 50 overall rating means the stock scores better than 50 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 50 means the stock is more attractive than 50 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

DBV TECHNOLOGIE/S ADR (DBVT) stock is trading at $2.81 as of 9:51 AM on Wednesday, Mar 18, an increase of $0.48, or 20.46% from the previous closing price of $2.33. The stock has traded between $2.76 and $3.10 so far today. Volume today is below average. So far 171,742 shares have traded compared to average volume of 741,694 shares.

To see the top 5 stocks in Biotechnology click here.

Read this article:
Industry Breakdown: Where Does DBV TECHNOLOGIE/S ADR (DBVT) Stock Fall in the Biotechnology Field? - InvestorsObserver

NEW YORK, March 18, 2020 /PRNewswire/ --

Trends, opportunities, and forecast in microsphere market to 2025 by end use industry (Composites, Medical Technology, Life Sciences and Biotechnology, Paints and Coatings, Cosmetics and Personal Care, and Others), product type (Hollow Microsphere and Solid Microsphere), material (Glass Microspheres, Polymer Microspheres, Ceramic Microspheres, Fly Ash Microspheres, Metallic Microspheres, and Others), and region (North America, Europe, Asia Pacific, and the Rest of the World)

Read the full report: https://www.reportlinker.com/p05876009/?utm_source=PRN

According to a new market report, the future of the global microsphere market looks promising with opportunities in the composites, medical technology, life science & biotechnology, and painting & coating industries. The global microsphere market is forecast to reach $4.7 billion by 2025 with a CAGR of 7.1% from 2020 to 2025. The major drivers for this market are the growing demand for higher efficiency and lightweight materials and superior structural and enhanced properties of microsphere over conventional fillers.Emerging trends, which have a direct impact on the dynamics of the industry, include continuous research and development to improve drug delivery system and development of biodegradable microspheres.

The study includes trends and forecast for the global microsphere market by product type, end use industry, material, and region as follows:

By End Use Industry [$M and Kilotons Shipment Analysis for 2014 2025]: Composites Medical Technology Life Sciences and Biotechnology Paints and Coatings Cosmetics and Personal Care Others

By Material Type ($M and Kilotons Shipment Analysis for 2014 2025): Glass Microsphere Polymer Microsphere Ceramic Microsphere Fly Ash Microsphere Metallic Microsphere Others

By Product [$M and Kilotons Shipment Analysis for 2014 2025]: Hollow Microsphere Solid Microsphere

By Region [$M and Kilotons Shipment Analysis for 2014 2025]: North America United States Canada Mexico Europe Germany France Spain Italy Asia Pacific China India Japan Korea The Rest of the WorldSome of the microsphere companies profiled in this report include 3M, Cospheric, Trelleborg, and AkzoNobel Expancel.

The analyst forecasts that glass microsphere will remain the largest material segment over the forecast period, as it provides lower viscosity, high melting point, and higher chemical resistance than other types of microsphere.

Composites is projected to remain the largest end use industry, and it is also expected to witness the highest growth during the forecast period due to increasing demand for lightweight materials in various end use industries.

North America will remain the largest region, and it is also expected to witness the highest growth over the forecast period due to increasing demand for composites in automobiles and growth in medical technology.

Some of the features of "Global Microsphere Market: Trends, Forecast and Competitive Analysis" Include: Market Size Estimates: Microsphere market size estimation in terms of value ($M) and volume (kilotons) shipment. Trends and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments. Segmentation Analysis: Microsphere market size by various segments, such as product type, material, and end use industry, in terms of value and volume shipment. Regional Analysis: Microsphere market breakdown by North America, Europe, Asia Pacific, and the Rest of the World. Growth Opportunities: Analysis on growth opportunities in different end use industries, product types, material types, and regions for the microsphere market. Strategic Analysis: This includes M&A, new product development, and competitive landscape for the microsphere market. Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers the following 11 key questions:________________________________________

Q.1 What are some of the most promising potential, high-growth opportunities for the global microsphere market by end use industry (Composites, Medical Technology, Life Sciences & Biotechnology, Paints & Coatings, Cosmetics & Personal Care, and Others), product type (Hollow Microsphere and Solid Microsphere), material (Glass Microspheres, Polymer Microspheres, Ceramic Microspheres, Fly Ash Microspheres, Metallic Microspheres, and Others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2 Which segments will grow at a faster pace and why?Q.3 Which regions will grow at a faster pace and why?Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the market?Q.5 What are the business risks and threats to the market?Q.6 What are emerging trends in this market and the reasons behind them?Q.7 What are some changing demands of customers in the market?Q.8 What are the new developments in the market? Which companies are leading these developments?Q.9 Who are the major players in this market? What strategic initiatives are being implemented by key players for business growth?

Read the full report: https://www.reportlinker.com/p05876009/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-microsphere-market-is-forecast-to-reach-4-7-billion-by-2025-with-a-cagr-of-7-1-from-2020-to-2025--301026041.html

SOURCE Reportlinker

See original here:
The global microsphere market is forecast to reach $4.7 billion by 2025 with a CAGR of 7.1% from 2020 to 2025 - Yahoo Finance

The Asia-Pacific bioinformatics market is projected to be the fastest growing regional market in the forecast period.

The introduction and adoption of cloud computing and nanopore technology are expected to offer numerous opportunities in the global bioinformatics market. The nanopore technology has been projected for getting used in the study of crop science, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins and small molecules with a range of applications in personalized medicine, and scientific research.

Download sample copy of this report@www.psmarketresearch.com/market-ort-sample

Bioinformatics is a discipline that deals with the retrieval, storage, processing, management and analysis of organic information through computational techniques. Bioinformatics plays an important role in drug innovation and improvement.

The involvement of bioinformatics in storing, retrieving, analyzing and forming biological information helps in efficiently managing enormous database associated with drug innovation and development.

On the basis of sector, the global bioinformatics market is fundamentally divided into forensic biotechnology, medical biotechnology, academics, environmental biotechnology, animal biotechnology and agriculture biotechnology. The medical biotechnology segment can be further classified into molecular medicine, drug development, gene therapy, clinical diagnostics and reproductive biotechnology.

Based on applications, the market is categorized into molecular phylo genetics, chemo informatics & drug design genomics, proteomics, transcriptomics and metabo lomics.

Pre-AccessInquiry at@www.psmarketresearch.com/send-enics-market

Bioinformatics technologies are used in various pharmaceutical and biotechnology sectors. They are mainly used in the medical sector, which is driven by the increasing use of bioinformatics for the drug development and discovery process.

Falling prices of DNA sequencing and increasing government initiatives to boost bioinformatics based life sciences research activities are the two major growth drivers of the global bioinformatics market. Some of the other drivers contributing to growth the of global bioinformatics market includes, increasing demand for bioinformatics as a consulting solution by pharmaceutical manufacturers and medical devices, in an effort to accelerate and improve manufacturing processes, with the increasing need for bioinformatics in data incorporation and warehousing.

Some of the key competitors within the global bioinformatics market include Tripos, LP, Affymetrix, Inc, Agilent Technologies, Illumina, Inc., Helicos Biosciences Corporation, IBM Life Sciences, Thermo Fisher Scientific Inc, Rosetta Inpharmatics LLC, Celera and others.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Go here to read the rest:
Current research: Bioinformatics Market trends, share, growth drivers and forecast report by 2030 - WhaTech Technology and Markets News

The report by HNY Research covers complete analysis of the Red Biotechnology report on a regional and global level. The report comprises several drivers and restraints of the Red Biotechnology. Likewise, it covers the complete segmentation analysis such as type, application, and region. This report provides information on key manufactures, industry chain analysis, competitive insights, and macroeconomic analysis. Global Red Biotechnology report provides the latest forecast market data, industry trends, and technological innovations. The in-depth view of Red Biotechnology industry on the basis of market size, market growth, opportunities, and development plans offered by the report analysis. The forecast information, SWOT analysis, and feasibility study are the energetic aspects studied in this report.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4372598

Manufacturer Detail

By Market Players:

By Application

By TypeAntibody, Nucleic Acid, Protein, Other

By F. Hoffmann-La RocheAmgen, Gilead Sciences, CSL, Pfizer

The study covers the production, sales, and revenue of various top players in the global Red Biotechnology market, therefore enabling customers to achieve thorough information of the competition and henceforth plan accordingly to challenge them and grasp the maximum market share. This report also focusses on significant statistics and information for the consumers to attain in-depth data of the Red Biotechnology and further Red Biotechnology growth. The up-to-date, complete product knowledge, end users, industry growth will drive the profitability and revenue. Red Biotechnology report by HNY Research studies the current state of the market to analyze the future opportunities and risks. Red Biotechnology report provides a 360-degree global market state. Primarily, the report delivers Red Biotechnology introduction, overview, market objectives, market definition, scope, and market size valuation.

Browse the complete report @ https://www.orbisresearch.com/reports/index/2020-2025-global-and-regional-red-biotechnology-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

Red Biotechnology report helps the end-users to understand the industry plans, growth factors, development strategies and policies implemented by leading Red Biotechnology players. This report analyses various facts and figures to grow the global Red Biotechnology revenue. A detailed explanation of Red Biotechnology potential consumers, market values, and the future scope are offered in this report. The key players of Red Biotechnology industry, their product portfolio, market share, industry profiles is studied in this report. The major market players are studied on the basis of gross margin, production volume, price structure, and market value. The competitive scenario among Red Biotechnology players will help the industry contenders in planning their policies. The report statistics covered in this report will be a beneficial guide to form the business growth.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4372598

On global level Red Biotechnology industry report by HNY Research segments the data on the basis of product type, applications, and regions. Regional Red Biotechnology segmentation analyses the market across regions such as North America, Europe, China, Japan, India, Middle East & Africa, South Africa, Southeast Asia, and South America. It also focusses on market dynamics, Red Biotechnology growth drivers, developing market segments and the market growth curve is offered based on past, present and future market statistics.

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Continue reading here:
2020-2025 Global and Regional Red Biotechnology Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report -...

DUBLIN--(BUSINESS WIRE)--The "Worldwide Wound Care Market Summary" report has been added to ResearchAndMarkets.com's offering.

Wound care is very much a challenge for both patients and healthcare providers.

The wound care market is a technologically enriched environment dedicated to advancing wound care therapies.

This report identifies a market opportunity for major sectors of this important market. A particular focus is given to biotechnology used in wound care, including advanced biodressings and negative pressure wound systems. The report focuses on wound care advancements, providing a table of newly approved wound care products for 2019.

The aging of the population and continued advances in biotechnology drive the wound care industry. It is the goal of new and existing product manufacturers to offer products designed to improve healing rates and prevent wound formation.

Market data in the report includes:

World Market

Total Market by Segment

Market Segments by Application

Market by Application

The report also contains current market size for the total wound care products market for the following countries and regions:

Advancements in biotechnology, biomaterials, and tissue engineering are expected to drive growth in the market during the report's forecast period. Growth is also being driven by the introduction of portable, single-use products in negative pressure wound therapy.

Worldwide Wound Care Market Summary provides an outline of the competitive market, including the following data points:

Industry participants have attempted to diversify their offerings by acquiring smaller companies with new and innovative technology. This move has created more competition among large wound care companies.

Key Topics Covered:

Chapter 1: Executive Summary

Chapter 2: Total Worldwide Wound Care Market Size, Forecast, and Competitive Analysis

Chapter 3: Wound Care Advancements

Chapter 4: Top Five Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/g31rxc

Follow this link:
Outlook into the Worldwide Wound Care Market to 2024 - Top 5 Competitors in the Global Industry - ResearchAndMarkets.com - Business Wire

Vir Biotechnology, Inc. (San Francisco, CA, USA) has entered into a collaboration with Biogen Inc. (Cambridge, MA, USA) for the development and clinical manufacturing of human monoclonal antibodies (mAbs) for the potential treatment of COVID-19, the disease caused by the SARS-CoV-2 virus.

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Vir has a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. The platform is used to identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. Vir engineers the fully human antibodies that it discovers to enhance their therapeutic potential. The company has identified a number of mAbs that bind to SARS-CoV-2, which were isolated from individuals who had survived a SARS (Severe Acute Respiratory Syndrome) infection. The company is conducting research to determine if its antibodies, or additional antibodies that it may be able to identify, can be effective as treatment and/or prophylaxis against SARS-CoV-2.

Due to the urgency of the situation, Vir and Biogen have begun work while a Clinical Development and Manufacturing Agreement is being negotiated. Subject to the completion of a definitive agreement, Biogen would continue cell line development, process development, and clinical manufacturing activities in order to advance the development of Virs proprietary antibodies.

These exceptional circumstances presented by the threat of COVID-19 require that we work with great urgency in the interest of the public good, said George Scangos, Ph.D., CEO, Vir. Biogen is one of the global leaders in cell line and process development for advanced biologics; tapping into their capabilities will provide us with a U.S. base for supply and manufacture of antibody therapies.

Similarly, Vir has also entered into a research collaboration agreement with the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC) to advance characterization and development of mAbs against coronaviruses. The joint project will augment ongoing efforts by both parties to identify antibodies that can be used to prevent or treat infection with existing and emerging viruses and help inform the development of vaccines. Vir and NIAID will work together to identify and optimize combinations of antibodies against coronaviruses, including SARS-CoV-2, SARS and MERS, as well as antibodies that may be effective across additional types of coronaviruses. The two parties will exchange antibodies and other materials for testing in combination and individually and, by mutual agreement, will perform in vivo animal studies to analyze immune responses.

This collaboration expands Virs efforts to characterize and develop antibody therapies against coronaviruses by allowing us to access the VRCs significant and broad research experience with coronaviruses, which is complementary to ours, said Herbert Skip Virgin, M.D., Ph.D., Chief Scientific Officer, Vir. This is one of multiple approaches we are taking to rapidly identify and test potential prophylactics and therapeutics for COVID-19 and we expect it to allow us to accelerate finding solutions to this urgent public health need.

Related Links:Vir Biotechnology, Inc. Biogen Inc.

Go here to read the rest:
Vir Biotechnology Partners with NIH and Biogen for Developing Coronavirus Antibodies - HospiMedica

COVID-19 continues to spread worldwide. The latest situation report from the World Health Organization (WHO) shows that there are now more than 125,000 confirmed cases of the disease and more than 4,600 deaths. Several biotech companies are racing to find a vaccine or a treatment for the rapidly spreading disease.

One of these companies is Vir Biotechnology (NASDAQ:VIR), which focuses on developing treatments for infectious diseases. Recently, Vir announced it was partnering up with Biogen (NASDAQ:BIIB) to develop and manufacture antibodies that could treat COVID-19. Given the gravity of the situation, the two companies decided to start working on this project while negotiating the terms of the deal.

Image Source: Getty Images.

On Jan. 22, Vir announced it was screening its library of antibodies to identify one that could be effective against COVID-19. The company had previous experience dealing with other coronaviruses, including Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). On Feb. 12, Vir announced it identified two antibodies with the potential to be effective against SARS-CoV-2, the virus that causes COVID-19.

The company partnered with other companies in its quest to beat the potentially deadly disease. Vir entered into an agreement with WuXi Biologics, a China-based biologics technology platform that helps companies develop and manufacture drugs.According to the terms of the deal, WuXi Biologics "will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development." WuXi Biologics will hold the right to market this treatment in China if it is approved, and Vir will market it in the rest of the world.

Continue reading here:
Biogen and Vir Biotechnology to Collaborate to Find a Treatment for the Coronavirus - The Motley Fool

NEW YORK Stocks that moved heavily or traded substantially on Thursday:

United Airlines Holdings Inc., down $12.26 to $37.08.

The U.S. is restricting travel from most of Europe for 30 days over the virus outbreak.

Boeing Co., down $34.24 to $154.84.

The airplane maker is reportedly freezing hiring and could draw down the remainder of a $13.8 billion loan.

Apache Corp., down 49 cents to $7.76.

The oil and gas company is cutting spending, reducing its rig count and drastically slashing its dividend.

Expedia Group Inc., down $11.63 to $65.04.

The economic impact from the virus outbreak is expected to inflict severe financial pain on travel-reliant companies.

United Parcel Service Inc., down $1.82 to $86.17.

The package delivery service said board member Carol Tome will take over from its retiring CEO.

Vir Biotechnology Inc., up $3.83 to $37.60.

The biotechnology company will work with Biogen to develop a potential treatment for COVID-19.

Live Nation Entertainment Inc., down $5.81 to $36. 20.

The concert promoter faces a dismal outlook as the virus outbreak cancels large public events.

Carnival Corp., down $6.78 to $14.97.

The companys Princess Cruises will suspend global operations through May 10 because of the virus outbreak.

See more here:
Live Nation, Carnival fall; Vir Biotechnology, rises - The Republic

This press release was orginally distributed by SBWire

Pune, India -- (SBWIRE) -- 03/16/2020 -- Data Bridge Market Research recently added "Agricultural biotechnology market by manufacturers, regions, type and application, forecast to 2027" in his database. This research report focus on complete assessment of market and contains future trend, growth factors, attentive opinions, facts, historical data, statistically supported and industry validated market data. Environmental concerns & regulatory guidelines regarding release of effluents through different industries. Agricultural biotechnology market comprehensive coverage of underlying economic and technological factors under key trend analysis.

Agricultural biotechnology market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 74.55 billion by 2027 growing at a CAGR of 9.94% in the above-mentioned forecast period. Escalated penetration of biotechnology, tissue culture, and molecular breeding and unique plant breeding is defining the success parameters of agricultural biotechnology market.

This agricultural biotechnology research report covers every aspects of the global market and presents it in easy to read format. The report also categories the industry into key geographical regions, sub regions, types and Applications. The global market study covers everything that a stakeholder needs to know about the Industry, complete with the sales, value, volume, market size and growth opportunities. The Market study covers everything that a stakeholder needs to know about the industry, complete with the sales, value, Volume, Market size and growth Opportunities.

Download Sample PDF Copy of Report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-agricultural-biotechnology-market

The major players covered in the agricultural biotechnology market report are KWS SAAT SE & Co. KGaA, ChemChina, Corteva., Limagrain, MITSUI & CO., LTD., AgPlenus ltd., Biomica, Evogene Ltd., Canonic ltd., Bayer AG, Valent BioSciences LLC, Nufarm Limited, Marrone Bio Innovations., Performance Plants Inc., ADAMA Ltd. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Major Topics Covered in this Report:

Chapter 1 Study Coverage

Chapter 2 Executive Summary

Chapter 3 Market Size by Manufacturers

Chapter 4 Production by Regions

Chapter 5 Consumption by Regions

Chapter 6 Market Size by Type

Chapter 7 Market Size by Application

Chapter 8 Manufacturers Profiles

Chapter 9 Production Forecasts

Chapter 10 Consumption Forecast

For More Insights Get Detailed TOC https://www.databridgemarketresearch.com/toc/?dbmr=global-agricultural-biotechnology-market

Global Agricultural Biotechnology Market Scope and Market Size

Agricultural biotechnology market is segmented on the basis of type, application, organism type, technology, and product. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of type, agricultural biotechnology market is segmented into molecular diagnostics, molecular markers, tissue culture, vaccines, genetic engineering, and others.On the basis of application, the agricultural biotechnology market is bifurcated into transgenic crops, flower culturing, nutritional supplements, biofuels, antibiotic development, vaccine development and others.On the basis of organism type, the agricultural biotechnology market is divided into plants, animals, microbes, and others.On the basis of technology, the agricultural biotechnology market is fragmented into genome editing tools, ribonucleic acid interference [RNAi], biochips, deoxy ribonucleic acid [DNA] sequencing, and synthetic biology.Based on the product, the agricultural biotechnology market is segregated into crop protection products, transgenic seeds, and synthetic biology-enables products. Crop protection products are further sub-categorized into biostimulants, and biopesticides. Transgenic seeds are further sub-segmented into soybean, fruits & vegetables, maize, cotton, and others.Inquiry For Customize Report With Discount At https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-agricultural-biotechnology-market

About Data Bridge Market ResearchData Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email: Corporatesales@databridgemarketresearch.com

For more information on this press release visit: http://www.sbwire.com/press-releases/global-agricultural-biotechnology-market-industry-size-growth-opportunities-outlook-and-forecast-2020-to-2027canonic-ltd-bayer-ag-valent-biosciences-llc-nufarm-limited-marrone-bio-innovations-performance-plants-inc-adama-ltd-1280300.htm

More here:
Global Agricultural Biotechnology Market Industry Size, Growth, Opportunities, Outlook and Forecast 2020 to 2027:Canonic Ltd., Bayer AG, Valent...

In this report, the global Agriculture Biotechnology market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Agriculture Biotechnology market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Agriculture Biotechnology market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2057155&source=atm

The major players profiled in this Agriculture Biotechnology market report include:

The key players covered in this studyADAMA Agricultural SolutionsVilmorinBayerBiocentury TransgeneCertisDow AgroSciencesEurofinsEvogeneGlobal Bio-chem TechnologySyngentaKWS SaatMarina BiotechMonsanto

Market segment by Type, the product can be split intoBiochipsDeoxy ribonucleic acid (DNS) sequencingGenome editing toolsRibonucleic acid interference (RNAI)Synthetic biology

Market segment by Application, split intoTransgenic crops marketSynthetic biology-enabled products market

Market segment by Regions/Countries, this report coversUnited StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2057155&licType=S&source=atm

The study objectives of Agriculture Biotechnology Market Report are:

To analyze and research the Agriculture Biotechnology market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Agriculture Biotechnology manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Agriculture Biotechnology market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the keyword market.

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2057155&source=atm

More here:
Agriculture Biotechnology Projected to Witness a Single-Digit CAGR During 2019-2025 - Daily Science

SOUTH SAN FRANCISCO, Calif., March 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation(Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that a consortium of medical schools led by the Icahn School of Medicine at Mount Sinaiis utilizing Fluidigm microfluidics technology to create an epigenetic test for early detection of the novel coronavirus that causes COVID-19. The spread of this disease has been declared a global pandemic by the World Health Organization.

Part of the Epigenetic CHaracterization and Observation (ECHO) program of the U.S.Defense Departments Defense Advanced Research Projects Agency (DARPA), the consortium is developing a testusing real-time PCR for host detection assays targeting epigenome and viral RNA for early-stage monitoring of potentially infected individuals.

Incorporating the Fluidigm Biomark HD system and the companys microfluidics technology, a single integrated fluidic circuit (IFC) can screen 192 samples across 24 different parallel processed assays to allow early detection of the virus infection. Labs will be able to generate more than 6,000 individual test results per day with just one hour of hands-on time, representing a scale and parallel processing of assays not possible using microwell plates.

The consortium led by the Icahn School of Medicine plans to submit the test for Emergency Use Authorization, in accordance with U.S. Food and Drug Administration (FDA) guidelines, for a high-throughput screening assay for COVID-19 based on robust real-time PCR. It will employ the high-throughput sample processing capacity of the Biomark HD coupled with parallel multi-assay interrogation of microfluidics.

Speed, scale and early detection are critical in addressing the spread of the COVID-19 pandemic, and the ability to rapidly screen a large number of samples will enhance capabilities in identification and management of infected individuals, including those who are asymptomatic, said Chris Linthwaite, President and CEO of Fluidigm. We believe the application of Fluidigm microfluidics technologies to epigenetic testing for COVID-19 has significant potential to increase the speed and capacity of these critical screening efforts.

Fluidigm is committed to supporting the efforts of the consortium and others in addressing the rapidly evolving global COVID-19 pandemic. We believe that partnering with other developers and labs seeking Emergency Use Authorization for tests utilizing our unique IFC technology has the potential to add significant testing capacity. Quick and reliable detection is crucial to combat this rapidly advancing pandemic.

Microfluidics technology generates more data and uses a fraction of expensive testing reagents per precious sample as compared with more traditional, microwell plate-based PCR technology. Fluidigm Biomark HD and microfluidics technology, in particular, enable the automated assembly of PCRs at the nanoscale level in a massively parallel manner.

We appreciate the unique expertise Fluidigm brings to this multi-institution, DARPA-supported effort to develop an early test for COVID-19, said Professor Stuart C. Sealfon, MD, principal investigator of the DARPA ECHO program and Director of the Center for Advanced Research on Diagnostic Assays and Chairman Emeritus of the Department of Neurology at the Icahn Sinai School of Medicine.

About FluidigmFluidigm(Nasdaq:FLDM) is an industry-leading biotechnology toolsprovider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visitfluidigm.com.

Fluidigm, theFluidigmlogo, Biomark, and CyTOF are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements for FluidigmThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the implementation of Fluidigm microfluidics technology and products by third parties and the anticipated benefits of, and applications and demand for, such products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to company research and development and distribution plans and capabilities; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affectingFluidigmbusiness and operating results is contained in Fluidigms Annual Report on Form 10-K for the year endedDecember 31, 2019, and in its other filings with theSecurities and Exchange Commission. These forward-looking statements speak only as of the date hereof.Fluidigmdisclaims any obligation to update these forward-looking statements except as may be required by law.

Contacts:

Media:Mark SpearmanSenior Director, Corporate Communications650 243 6621mark.spearman@fluidigm.com

Investors:Agnes LeeVice President, Investor Relations650 416 7423agnes.lee@fluidigm.com

Go here to see the original:
Consortium of Medical Schools Led by Mount Sinai Fast-Tracking COVID-19 Detection Test Utilizing Fluidigm Microfluidics Technology - GlobeNewswire